AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01739348
Drug: Placebo (Part I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single placebo tablet matching verubecestat treatment once daily, taken orally
Trial: NCT00823108
Drug: GIK
RxNorm normalized name: Surgikos Tip Cleaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 hour infusion of GIK solution
Trial: NCT01740726
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
Trial: NCT01769755
Drug: Vehicle Controlled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
Trial: NCT01825031
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg once daily for 5 days
Trial: NCT01670266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01974609
Drug: Narcotic
RxNorm normalized name: narcotic antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone 5mg + acetaminophen 325 mg
Trial: NCT01974609
Drug: non-narcotic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 600mg + acetaminophen 325 mg
Trial: NCT01541293
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
Trial: NCT00569530
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
Trial: NCT02788864
Drug: Arterakine (DHA/piperaquine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
Trial: NCT02788864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
Trial: NCT01680172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of liquid placebo solution taken by mouth
Trial: NCT03606824
Drug: Pitavastatin and levothyroxine
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
Trial: NCT01273064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo).
Trial: NCT03969888
Drug: Placebo ABBV-3067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet taken orally.
Trial: NCT03969888
Drug: Placebo ABBV-2222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule taken orally.
Trial: NCT00143507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00083278
Drug: MDX-010
RxNorm normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00177671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02852083
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg twice daily p.o.
Trial: NCT03947034
Drug: Drugs inducing hyperammonemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs susceptible to induce metabolic toxicities such as hyperammonemia
Trial: NCT04002700
Drug: Typical Antipsychotics
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
Trial: NCT04002700
Drug: Atypical Antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
Trial: NCT00780039
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Trial: NCT01178931
Drug: Crinone 8% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal-1x90mg
Trial: NCT00933348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
Trial: NCT01239680
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1 liter once over 6 hours
Trial: NCT01239680
Drug: Placebo (for Glutamine)
RxNorm normalized name: glutamine Powder for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Intravenously in 1 liter Lactated Ringer's
Trial: NCT03617432
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Trial: NCT03617432
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Trial: NCT00855582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
Trial: NCT01531179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 3 months
Trial: NCT04208932
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Serotonin Reuptake Inhibitors
Trial: NCT01013753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
Trial: NCT01599962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single administration
Trial: NCT04163263
Drug: BOS-356
RxNorm normalized name: BOS TAURUS EYE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel
Trial: NCT04163263
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel
Trial: NCT02260986
Drug: Placebo (for Dupilumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Trial: NCT00853385
Drug: CP 690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
Trial: NCT00853385
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
Trial: NCT03383679
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: treatment with capecitabine
Trial: NCT00191919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01001104
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
Trial: NCT01001104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by SC injection, QW for 12 weeks.
Trial: NCT01381510
Drug: 5-alpha Reductase Inhibitor (5ARI)
RxNorm normalized name: 5.alpha.-hydroxy laxogenin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 5ARI: Either dutasteride or finisteride
Trial: NCT02397837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo match study drug
Trial: NCT01055912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
Trial: NCT01590615
Drug: Anti-HBV nucleoside/nucleotide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
Trial: NCT03852576
Drug: KSP/QRH dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KSP-QRH-E3-IRDye800 (Peptide 919288G)
Trial: NCT03695094
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
Trial: NCT02323334
Drug: LY3202626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT02323334
Drug: Placebo (Part A, B, C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT02786667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months treatment with Placebo up to 8 mg per day with a titration period for one month
Trial: NCT01834261
Drug: Syntocinon Nasal Spray, 40IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Trial: NCT01834261
Drug: Syntocinon Placebo Formulation, 40IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
Trial: NCT03745781
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT04038125
Drug: Ozurdex Drug Implant Product
RxNorm normalized name: Ozurdex Drug Implant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Ozurdex injection
Trial: NCT00005585
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00005585
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
Trial: NCT00005585
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
Trial: NCT00005585
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
Trial: NCT03228914
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
Trial: NCT04504760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo will be administered orally.
Trial: NCT04504760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of placebo will be administered orally.
Trial: NCT01666600
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
Trial: NCT02580344
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
Trial: NCT01158404
Drug: LY900009 - Dose Confirmation Phase (Part B)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met.
Trial: NCT01692756
Drug: Kenalog or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01692756
Drug: Kenalog then Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01692756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00650624
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
Trial: NCT00650624
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
Trial: NCT01573377
Drug: Ethinylestradiol and Cyproterone Acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
Trial: NCT00650624
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
Trial: NCT00650624
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet by mouth once daily in the morning for 6 weeks
Trial: NCT00528385
Drug: Spironolactone (Spironol) 25 mg
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
Trial: NCT04556851
Drug: HSK7653 10 mg Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
Trial: NCT04556851
Drug: HSK7653 25 mg Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
Trial: NCT04556851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
Trial: NCT03986268
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
Trial: NCT00899847
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
Trial: NCT00899847
Drug: Solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
Trial: NCT00899847
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
Trial: NCT00899847
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
Trial: NCT04626778
Drug: Peroxyl Mouthwash
RxNorm normalized name: Peroxyl Mouthwash Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash
Trial: NCT04626778
Drug: Placebo Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash
Trial: NCT03073057
Drug: Symbicort Turbuhaler
RxNorm normalized name: Symbicort Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT02851914
Drug: Tricyclic Antidepressants (TCA)
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
Trial: NCT03727867
Drug: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral EGFR TKI begins on day 1 and continues until disease progresses.
Trial: NCT01810952
Drug: Lispro insulin
RxNorm normalized name: Lispro insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
Trial: NCT01810952
Drug: NPH Insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
Trial: NCT00221104
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00876343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally once daily, 6 weeks
Trial: NCT00543465
Drug: MK0782
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02411955
Drug: Tazorac®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
Trial: NCT02411955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.